uniQure (NASDAQ:QURE) Upgraded by StockNews.com to “Sell” Rating

uniQure (NASDAQ:QURE) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Wednesday.

Other research analysts have also issued research reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. HC Wainwright boosted their price target on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Stifel Nicolaus increased their price target on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Finally, The Goldman Sachs Group raised their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.00.

uniQure Price Performance

QURE stock opened at $16.21 on Wednesday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm’s fifty day moving average is $14.49 and its 200 day moving average is $9.14. The firm has a market cap of $790.12 million, a P/E ratio of -3.27 and a beta of 0.38. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Research analysts predict that uniQure will post -3.75 earnings per share for the current year.

Insider Transactions at uniQure

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. This represents a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.74% of the stock is owned by insiders.

Institutional Investors Weigh In On uniQure

Several hedge funds and other institutional investors have recently modified their holdings of QURE. Marshall Wace LLP purchased a new position in shares of uniQure during the 2nd quarter valued at $175,000. Algert Global LLC purchased a new position in uniQure during the 2nd quarter valued at about $176,000. Cubist Systematic Strategies LLC boosted its position in uniQure by 130.9% during the second quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 14,454 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of uniQure by 49.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 271,346 shares of the biotechnology company’s stock worth $1,338,000 after acquiring an additional 89,400 shares in the last quarter. Finally, Ballentine Partners LLC acquired a new position in shares of uniQure during the third quarter worth $116,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.